Introduction to the Tennessee Gabapentin Dementia Lawsuit
- Tennessee Gabapentin Dementia Lawsuit: Significant new research as well as patient reports have raised concerns that long-term or repeated gabapentin use is linked to dementia, mild cognitive impairment, memory loss, confusion, and other cognitive problems
- Criteria for a Nashville Gabapentin Dementia Lawsuit: If you or a loved one experienced early-onset dementia after taking gabapentin (Neurontin), contact Nashville Gabapentin Dementia Lawsuit Lawyer Timothy L. Miles today. You may be eligible for a Gabapentin Dementia Lawsuit and possibly entitled to substantial compensationin a Gabapentin Dementia Lawsuit . (855) 846–6529 or tmiles@timmileslaw.com.
- Gabapentin Dementia Lawsuit Lawyer: Represents individulas who individuals who took Gabapentin and subsequently suffering a diagnosis of early-onset dementia, mild cognitive impairment, or significant cognitive decline.
- Cognitive Risks of Gabapentin: Long-term Neurontin use, including multiple prescriptions, off-label prescribing, and subsequently suffering a diagnosis of early-onset dementia, mild cognitive impairment, or significant cognitive decline.
- Gabapentin Dementia Lawsuit: Significant new research as well as patient reports have raised concerns that long-term or repeated gabapentin use is linked to dementia, mild cognitive impairment, memory loss, confusion, and other cognitive problems.
- Gabapentin Dementia Lawsuit: Significant new research as well as patient reports have raised concerns that long-term or repeated gabapentin use is linked to dementia, mild cognitive impairment, memory loss, confusion, and other cognitive problems.
- Current Claim: Plaintiffs are investigating whether gabapentin may increase the risk of dementia, mild cognitive impairment, and serious memory loss.
- Primary Cause of Action: Failure to warn doctors and patients about cognitive risks, especially after years of off-label use and emerging safety research.
- Litigation Landscape: Early investigation. No nationwide gabapentin dementia MDL has been created as of September 2026.


